Atara Biotherapeutics Ownership
| ATRA Stock | USD 7.14 0.03 0.42% |
Shares in Circulation | First Issued 2013-03-31 | Previous Quarter 10.7 M | Current Value 10.9 M | Avarage Shares Outstanding 2.7 M | Quarterly Volatility 2.4 M |
Atara Stock Ownership Analysis
About 22.0% of the company shares are held by company insiders. The company has price-to-book (P/B) ratio of 1.97. Some equities with similar Price to Book (P/B) outperform the market in the long run. Atara Biotherapeutics recorded a loss per share of 2.26. The entity had not issued any dividends in recent years. The firm had 1:25 split on the 20th of June 2024. Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. The company was incorporated in 2012 and is headquartered in South San Francisco, California. Atara Biotherap operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 578 people. For more info on Atara Biotherapeutics please contact Pascal DVM at 805 623 4211 or go to https://www.atarabio.com.Besides selling stocks to institutional investors, Atara Biotherapeutics also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Atara Biotherapeutics' stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Atara Biotherapeutics' strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Atara Biotherapeutics Quarterly Liabilities And Stockholders Equity |
|
Atara Biotherapeutics Insider Trades History
About 22.0% of Atara Biotherapeutics are currently held by insiders. Unlike Atara Biotherapeutics' institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Atara Biotherapeutics' private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Atara Biotherapeutics' insider trades
Atara Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Atara Biotherapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Atara Biotherapeutics backward and forwards among themselves. Atara Biotherapeutics' institutional investor refers to the entity that pools money to purchase Atara Biotherapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | State Street Corp | 2025-03-31 | 25.3 K | Marshall Wace Asset Management Ltd | 2024-12-31 | 25 K | Birchview Capital, Lp | 2024-12-31 | 22 K | Gsa Capital Partners Llp | 2025-03-31 | 19.4 K | Renaissance Technologies Corp | 2025-03-31 | 17.4 K | Fmr Inc | 2025-03-31 | 17.2 K | Bridgeway Capital Management, Llc | 2025-03-31 | 14 K | Cubist Systematic Strategies, Llc | 2024-12-31 | 12.7 K | Northern Trust Corp | 2024-12-31 | 11.2 K | Ecor1 Capital, Llc | 2024-12-31 | 532.1 K | Redmile Group, Llc | 2024-12-31 | 441.7 K |
Atara Biotherapeutics Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Atara Biotherapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Atara Biotherapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Atara Biotherapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Atara Biotherapeutics Outstanding Bonds
Atara Biotherapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Atara Biotherapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Atara bonds can be classified according to their maturity, which is the date when Atara Biotherapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| ATT INC 535 Corp BondUS04650NAB01 | View | |
| US04650YAA82 Corp BondUS04650YAA82 | View |
Atara Biotherapeutics Corporate Filings
| 21st of May 2025 Other Reports | ViewVerify | |
F4 | 20th of May 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
8K | 16th of May 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
| 28th of April 2025 Other Reports | ViewVerify |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Atara Biotherapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Atara Biotherapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Atara Biotherapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Atara Biotherapeutics Stock:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Atara Biotherapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. For information on how to trade Atara Stock refer to our How to Trade Atara Stock guide.You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Atara Biotherapeutics. If investors know Atara will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Atara Biotherapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.26) | Revenue Per Share | Quarterly Revenue Growth 2.588 | Return On Assets | Return On Equity |
The market value of Atara Biotherapeutics is measured differently than its book value, which is the value of Atara that is recorded on the company's balance sheet. Investors also form their own opinion of Atara Biotherapeutics' value that differs from its market value or its book value, called intrinsic value, which is Atara Biotherapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Atara Biotherapeutics' market value can be influenced by many factors that don't directly affect Atara Biotherapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Atara Biotherapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Atara Biotherapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Atara Biotherapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.